Morphic Holding, Inc. (NASDAQ:MORF) Director Fund V. L.P. Omega sold 4,436 shares of Morphic stock in a transaction that occurred on Friday, February 19th. The shares were sold at an average price of $35.57, for a total transaction of $157,788.52. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
MORF traded down $0.10 during trading on Tuesday, hitting $34.33. The stock had a trading volume of 3,416 shares, compared to its average volume of 139,777. The company has a market capitalization of $1.07 billion, a PE ratio of -21.87 and a beta of 1.01. Morphic Holding, Inc. has a twelve month low of $9.90 and a twelve month high of $41.00. The stock has a 50 day simple moving average of $33.69 and a two-hundred day simple moving average of $29.90.
Several equities analysts recently issued reports on the stock. Zacks Investment Research raised shares of Morphic from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Tuesday, November 17th. Royal Bank of Canada lifted their price objective on shares of Morphic from $35.00 to $50.00 and gave the company an “outperform” rating in a report on Tuesday, February 2nd.
Morphic Company Profile
Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral avÃ6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a4Ã7 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD).
Read More: Dividend Kings
Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.